--- title: "Aligos Presents Promising Data For Pevifoscovir Sodium In Treating Hepatitis B" type: "News" locale: "en" url: "https://longbridge.com/en/news/287774756.md" description: "Aligos Therapeutics Inc. presented positive data on Pevifoscorvir sodium for treating chronic hepatitis B at the EASL congress. The drug showed antiviral activity, reducing HBV levels in untreated patients. A potential functional cure regimen may be possible in combination with an antisense oligonucleotide agent. The company is also exploring treatments for hepatitis delta virus and metabolic dysfunction-associated steatohepatitis. ALGS stock closed at $5.74, slightly down, but rose to $5.75 in pre-market trading." datetime: "2026-05-27T12:55:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287774756.md) - [en](https://longbridge.com/en/news/287774756.md) - [zh-HK](https://longbridge.com/zh-HK/news/287774756.md) --- # Aligos Presents Promising Data For Pevifoscovir Sodium In Treating Hepatitis B (RTTNews) - Aligos Therapeutics Inc. (ALGS), a clinical-stage biopharmaceutical company, on Wednesday presented positive data from ten presentations evaluating Pevifoscorvir sodium in treating chronic hepatitis B and other ongoing studies at the European Association for the Study of the Liver (EASL) congress, 2026. Hepatitis B is one of the most common chronic viral infections, with over 2.34 million carriers worldwide. The virus is also the primary cause of liver cancer. The Hepatitis B virus (HBV) is diagnosed by detecting certain antigens, such as the hepatitis B e-antigen (HbeAg) or the hepatitis B surface antigen (HbsAg). Pevifoscorvir sodium is an oral, small molecule, capsid assembly modulator-enhancer (CAM-E), that has shown antiviral activity by reducing the covalent closed circular DNA (cccDNA) reservoir, according to long-term follow up data from the Phase 1 study. The drug is being evaluated in combination with tenofovir disoproxil fumarate in the Phase 2 B-SUPREME study, in untreated HBeAg+ and HBeAg- adult patients of chronic HBV infection. The new presented data from studies showed that untreated HbeAg+ patients who completed 96 weeks of pevifoscorvir sodium monotherapy, followed by nucleotide-analog therapy, showed decreased HBV and HBV RNA levels during the 24-week follow-up period. Additionally, HbsAg+ patients on the drug showed a reduction in HBV levels to below 3000 IU/ml, suggesting a functional cure regimen may be possible in combination with an antisense oligonucleotide (ASO) agent such as ALG-170675, developed with partner Amoytop. Preclinical in vitro data for ALG-001075, the active parent moiety of pevifoscorvir sodium, demonstrated potent and durable suppression of HBeAg, HBsAg, and intracellular HBV RNAs with effects persisting after treatment withdrawal, indicating a reduction in cccDNA levels and transcriptional activity. The drug also showed additive synergistic antiviral effect with ALG-170675, a developing, potentially first-in-class ASO agent. The company is also exploring ASO candidates for the treatment of the hepatitis delta virus (HDV), and a THR-Beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). ALGS closed Tuesday at $5.74, down 0.35%. In the pre-market, the stock is trading at $5.75, up 0.16%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [ALGS.US](https://longbridge.com/en/quote/ALGS.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [688278.CN](https://longbridge.com/en/quote/688278.CN.md) - [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md) ## Related News & Research - [Medicare is about to change a drug program that held down the cost of premiums. Here's what to know.](https://longbridge.com/en/news/294391519.md) - [Aligos completes enrollment in Phase 2 B-SUPREME trial for chronic hepatitis B drug pevifoscorvir sodium](https://longbridge.com/en/news/292485727.md) - [Aligos Q2 FY26 net loss narrows 91% to $1.5 million](https://longbridge.com/en/news/295103944.md) - [Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates](https://longbridge.com/en/news/283025639.md) - [Aligos and Xiamen Amoytop sign deal for HBV therapy](https://longbridge.com/en/news/283126492.md)